BioCardia (BCDA) director receives 8,000 stock options exercisable at $1.20
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioCardia, Inc. director Simon H. Stertzer received a grant of stock options as part of his compensation. He was awarded options to acquire 8,000 shares of BioCardia common stock at an exercise price of $1.20 per share, expiring on July 6, 2036. All of these options vest and become exercisable on the one-year anniversary of the grant date, as long as he continues as a service provider through that date. Following this grant, he holds stock options covering a total of 23,573 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
STERTZER SIMON H
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 8,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 23,573 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 8,000 options
Exercise price: $1.20 per share
Expiration date: July 6, 2036
+1 more
4 metrics
Stock options granted
8,000 options
Grant to director on July 6, 2026
Exercise price
$1.20 per share
Strike price of granted options
Expiration date
July 6, 2036
Option term for 8,000-share grant
Total options after grant
23,573 shares
Director’s derivative holdings following transaction
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.2000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-06T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"shares are subject to the option vesting and becoming exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did BioCardia (BCDA) director Simon H. Stertzer report on this Form 4?
Simon H. Stertzer reported receiving a grant of stock options to acquire 8,000 shares of BioCardia common stock. The options were awarded as a compensation-related grant, not an open-market purchase or sale of existing shares.
What are the key terms of the BioCardia (BCDA) stock options granted to Stertzer?
The grant covers 8,000 stock options with an exercise price of $1.20 per share and an expiration date of July 6, 2036. These options give Stertzer the right to buy BioCardia common stock at that fixed price.
When do Simon H. Stertzer’s BioCardia (BCDA) options vest?
One hundred percent of the 8,000 options vest and become exercisable on the one-year anniversary of the grant date. Vesting is conditional on Stertzer continuing as a service provider through that anniversary date.
How many BioCardia (BCDA) derivative securities does Stertzer hold after this grant?
After this grant, Stertzer holds derivative securities representing 23,573 shares of BioCardia common stock. This total reflects his stock option position following the 8,000-option award reported in the filing.
Was the BioCardia (BCDA) Form 4 transaction a market buy or sell?
No, the transaction was a compensation-related stock option grant coded as an acquisition. It did not involve an open-market purchase or sale of BioCardia common stock by Stertzer.